Abstract：
UNASSIGNED: In rare cases, zolpidem administration has been found to paradoxically improve cognition in patients with brain injury in disorders of consciousness.
UNASSIGNED: Two minimally conscious plus (MCS+) patients at baseline, a 24-year-old woman 8 weeks post-traumatic brain injury (TBI) and 23-year-old man 6 weeks post-TBI, demonstrated behavioral improvements after off-label, single-dose administration of 10 mg of zolpidem.
UNASSIGNED: The patients demonstrated improved cognition on Coma Recovery Scale-Revised assessment after ingesting zolpidem. In particular, speech was substantially restored as one patient recovered functional communication and both demonstrated intelligible verbalizations for the first-time post-injuries following zolpidem. Overall, evidence is limited regarding the underlying mechanisms of various cognitive improvements in zolpidem response although studies incorporating neuroimaging are promising. The outcomes and similarities between these cases contribute to the current literature and highlight the need for rigorous studies in the future to guide zolpidem trials in patient care for those with DOC.
UNASSIGNED: Two minimally conscious plus (MCS+) patients at baseline, a 24-year-old woman 8 weeks post-traumatic brain injury (TBI) and 23-year-old man 6 weeks post-TBI, demonstrated behavioral improvements after off-label, single-dose administration of 10 mg of zolpidem.
UNASSIGNED: The patients demonstrated improved cognition on Coma Recovery Scale-Revised assessment after ingesting zolpidem. In particular, speech was substantially restored as one patient recovered functional communication and both demonstrated intelligible verbalizations for the first-time post-injuries following zolpidem. Overall, evidence is limited regarding the underlying mechanisms of various cognitive improvements in zolpidem response although studies incorporating neuroimaging are promising. The outcomes and similarities between these cases contribute to the current literature and highlight the need for rigorous studies in the future to guide zolpidem trials in patient care for those with DOC.
摘要：
■在极少数情况下，已经发现唑吡坦给药矛盾地改善患有意识障碍的脑损伤患者的认知。
■两名处于基线状态的最低意识加（MCS）患者，一名24岁的女性在创伤性脑损伤（TBI）后8周，一名23岁的男性在TBI后6周，在标签外表现出行为改善，单剂量给药10毫克唑吡坦。
■服用唑吡坦后，患者在昏迷恢复量表修订评估中表现出认知改善。特别是,由于一名患者恢复了功能性沟通,并且在唑吡坦治疗后首次出现可理解的言语表达,言语基本恢复.总的来说,关于唑吡坦反应各种认知改善的潜在机制的证据有限,尽管结合神经影像学的研究很有前景.这些病例之间的结果和相似性有助于目前的文献，并强调未来需要严格的研究来指导唑吡坦在DOC患者护理中的试验。
■两名处于基线状态的最低意识加（MCS）患者，一名24岁的女性在创伤性脑损伤（TBI）后8周，一名23岁的男性在TBI后6周，在标签外表现出行为改善，单剂量给药10毫克唑吡坦。
■服用唑吡坦后，患者在昏迷恢复量表修订评估中表现出认知改善。特别是,由于一名患者恢复了功能性沟通,并且在唑吡坦治疗后首次出现可理解的言语表达,言语基本恢复.总的来说,关于唑吡坦反应各种认知改善的潜在机制的证据有限,尽管结合神经影像学的研究很有前景.这些病例之间的结果和相似性有助于目前的文献，并强调未来需要严格的研究来指导唑吡坦在DOC患者护理中的试验。
